Lee Chan Henry 4

What Happened

• Lee Chan Henry, Senior Vice President and General Counsel of BeOne Medicines (ONC), exercised stock option/derivative awards and sold the resulting American Depositary Shares (ADS). On March 11, 2026 he acquired 110 ADS at $194.47 ($21,392), 133 ADS at $213.32 ($28,372), and 98 ADS at $159.03 ($15,585) — total acquisition cost $65,349. Those exercises converted a total of 4,433 ordinary shares into 341 ADS (1 ADS = 13 ordinary shares).
• The same day he sold all 341 ADS in an open-market transaction at $300.00 per ADS for total proceeds of $102,300. Net proceeds (sale proceeds minus exercise costs) were about $36,951.

Key Details

• Transaction date: March 11, 2026 (Form 4 filed March 13, 2026 — appears timely).
• Acquisitions (exercise of derivatives): 110 ADS @ $194.47 ($21,392); 133 ADS @ $213.32 ($28,372); 98 ADS @ $159.03 ($15,585). These correspond to ordinary share amounts of 1,430; 1,729; and 1,274 respectively (total 4,433 ordinary shares).
• Disposition (sale): 341 ADS @ $300.00 = $102,300. Sale effected pursuant to a Rule 10b5-1 trading plan adopted May 14, 2025 (Footnote F2).
• Footnotes: 1 ADS = 13 ordinary shares (F1). Vesting schedules for the underlying awards are noted (F4–F6 — multi-year vesting with initial 25% cliff and monthly installments thereafter).
• Shares owned after transaction: not specified in the provided excerpt of the filing.

Context

• This sequence shows exercises of options/derivatives followed by an immediate open-market sale of the resulting ADS; functionally similar to an exercise-and-sell (often used to cover exercise cost and taxes). The filing documents both the extinguishment/disposition of derivative instruments and the acquisition of the underlying ADS.
• The sale was executed under a pre-established Rule 10b5-1 plan, which typically indicates planned, rule-compliant sales rather than ad-hoc trading. No inference about personal sentiment or company outlook should be drawn from routine option exercises and plan-based sales.